Background: Cancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands of lives. However, many people cannot benefit from rituximab treatment because of drug resistance or side effects. Methods: In this study, a 13-nm rituximab-conjugated magnetic nanoparticle was developed as a therapeutic nanoprobe targeting CD20 overexpressing malignant lymphoma cells to enhance the treatment effects of rituximab. The magnetic cores (2,3-dimercaptosuccinicacid modified Fe 3 O 4 nanoparticles, Fe 3 O 4 @DMSA) of the nanoprobes with an average diameter of 6.5 nm were synthesized using a co-precipitation method. Rituximab was then conjugated on the surface of Fe 3 O 4 @DMSA using a cross-linking agent (carbodiimide/N-hydroxysulfosuccinimide sodium salt). Based on theoretical calculations, approximately one antibody was coupled with one nanoparticle, excluding the multivalent antibody effect. 
Introduction
Targeted therapy has substantial promise in tumor treatment, [1] [2] [3] [4] but its efficacy is limited by the need to deliver the drug or antibody in sufficient quantities to the tumor tissue. 5 Over the past decades, researchers have been studying monoclonal antibodies in the clinical application of cancer. 3, 6, 7 Monoclonal antibodies such as rituximab targeted against the CD20 antigen on the membrane of B-lymphocytes in B-cell non-Hodgkin's lymphoma (NHL) showed a satisfactory curative effect in the clinical treatment of NHL. Rituximab (trade names Rituxan, MabThera, and Zytux) is a chimeric monoclonal antibody approved by the Food and Drug Administration of the United States in 1997.
Rituximab exhibits multiple anti-NHL activities, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, growth inhibition, and apoptosis. 3, 6, 7 It has been shown that after binding with rituximab, CD20 on lipid rafts is redistributed to a large lipid raft domain, 9 known to be a signal transduction center. Subsequent signaling events have been observed in rituximab-treated lymphoma cells in vitro, including downregulation of Bcl-2 levels, activation of the Src family members, and regulation of cellular calcium. [10] [11] [12] Rituximab can enhance the sensitization of lymphoma cells to chemotherapeutic drugs. 8 , 13 Bubien et al 14 demonstrated that transfection of CD20 into some CD20-negative cell lines can induce cytosolic calcium release. Furthermore, Tan et al 15 used a quartz crystal microbalance technique to demonstrate that rituximab induced intake of Ca 2+ ions by Raji cells. This provides valuable information on CD20 as a calcium ion channel on cell membranes. Daniels et al 16 identified that rituximab binding to CD20 causes disequilibrium of intracellular calcium homeostasis and plays an essential role in the process of rituximab-driven caspase-independent apoptosis. In the long term, rituximab is the first-line therapy for B-cell NHL in clinical practice.
NHL is a heterogeneous group of malignant tumors originating in the lymphatic system, 17 its incidence is rising annually. The incidence rate of lymphoma is 4.2% among the cancer registration areas in China. Both the incidence and mortality of lymphoma were ranked ninth in male population in China in 2013. 18 In addition, there were an estimated 72,240 new cases of NHL and around 20,140 deaths in the United States in 2017, 19 showing little change from those in 2016 20 and 2015. 21 In the European Union, about 93.4/1,000 newly diagnosed cases and 37.9/1,000 patients died due to NHL in 2012. 22 Many patients relapse after combination therapy with rituximab and chemotherapy. 23 It has thus become a great challenge to improve therapeutic approach in NHL.
To date, magnetic nanoparticles and magnetic nanoprobes, as a kind of emerging nanomaterial, have been actively investigated as an application in nanomedicine, including magnetic gene and drug delivery, 24 magnetic resonance imaging (MRI), 24, 25 thermal therapy, 24, 26 cell labeling, 27, 28 and in vitro bio-separation. 24, 29 For example, Huh et al 30 successfully conjugated the cancer-targeting antibody, Herceptin, to the surface of superparamagnetic iron oxide to form MRI probes. Their study reveals that targeted detection in a mouse xenograft human cancer model by in vivo MRI is achievable. They then designed and synthesized manganese-doped iron oxide nanoparticles for conjugation with antibodies. 31 The nanoprobes showed enhanced MRI sensitivity for detection of small tumors in mice in vivo. Chiu et al 32 developed a construct by grafting rituximab molecules onto liposome membranes to enhance its activity. Nevertheless, few studies have used these as theranostic agents in the simultaneous imaging and treatment of NHL. The advantages of magnetic nanoprobes include accurate diagnosis of NHL at an early stage by clinical MRI and enhancement of curative effects.
Here, we successfully prepared 2,3-dimercaptosuccinic acid (DMSA)-modified iron oxide nanoparticles (Fe 3 O 4 @ DMSA) via a simple co-precipitation technique. The nanoprobes (Fe 3 O 4 @DMSA@Ab) were prepared to target CD20-overexpressing malignant lymphoma cells. CD20-positive Raji cells were selected as the target cell line and CD20-negative K562 cells were chosen as the control. The feasibility of using these nanoprobes as targeted MRI and therapeutic agents was investigated at the cellular level. Cytotoxicity and cellular specificity were evaluated and cell target binding was monitored by measuring MR signal on a clinical 1.5T MRI scanner changes after incubating the nanoprobes at different amounts with CD20-positive Raji cells. CD20 binding after Fe 3 O 4 @DMSA@Ab treatment can be induced by the short-range interaction of multiple nanoprobes, which can be strengthened in the presence of a magnetostatic field (MF). The mechanism of Raji cell apoptosis induced by Fe 3 O 4 @DMSA@Ab nanoprobes might be related to CD20 cluster formation, flux of Ca 
Materials and methods Materials
All reagents and solvents were obtained from commercial suppliers and were used without further purification. Then aqueous ammonia solution (40 mL) was added to the mixture rapidly under vigorous stirring at 72°C. OA (9 mL) was dropped into the reaction system after 5 minutes. After 3 hours, the resulting sediment was washed with ethyl alcohol and distilled water until neutrality was achieved. The OA-coated magnetite particles (Fe 3 O 4 @OA) were dispersed in n-hexane.
DMSA (200 mg) was dissolved in acetone (100 mL) in a 500 mL three-necked bottle. Meanwhile, Fe 3 O 4 @OA nanoparticles were dispersed in n-hexane (100 mL) at a concentration of 4 mg/mL. The miscible liquids were heated up to 60°C and refluxed for 5 hours. A black precipitate (Fe 3 O 4 @DMSA nanoparticles) was obtained by magnetic separation and washed several times with double-distilled water. The Fe 3 O 4 @DMSA nanoparticles were dispersed in 50 mL double-distilled water by ultrasound. The solution was poured into a dialysis bag in water for 72 hours. The final sample (Fe 3 O 4 @DMSA) was filtrated with a 0.22 µm membrane. The phenanthroline method for determining the concentration of ferric ion in Fe 3 O 4 @DMSA nanoparticles has been detailed in the Supplementary materials ( Figure S1A ). The purified solution was stored at 4°C.
synthesis of Fe 3 O 4 @DMsa@ab magnetic nanoprobes
The nanoparticles of Fe 3 O 4 @DMSA were coupled with antibody via covalent bond formation between the free carboxylic groups of DMSA and the amine groups of rituximab. EDC (10 µg/µL, 10 µL) and sulfo-NHS (10 µg/µL, 5 µL) were added to 0. 
live/dead cell staining
The treated Raji and K562 cells were also stained with AO and EB. After treatment with rituximab (23.5 µg/mL), 
In vitro TeM imaging of cells cultured with Fe 3 O 4 @DMsa@ab nanoprobes
The ultrastructure of cells was also observed by TEM (JEM-2000EX; JEOL) after culturing with Fe 3 O 4 @DMSA@ Ab nanoprobes. For control experiments, medium without nanoparticles was used. As above, the cells were washed and collected after co-culture. The cell clusters were then fixed with 2.5% glutaraldehyde for 24 hours and then treated with 1% osmium tetroxide for 1.5 hours. The cell clusters were dehydrated through ethanol at a series of different concentrations (20%, 30%, 40%, 50%, 60%, 70%, 90%, and 100%). The cell clusters were then soaked in propylene oxide (twice for 15 minutes each) and a mixture of propylene oxide and araldite resin overnight. Finally, the cell clusters were infiltrated with fresh araldite resin (three times, 3-4 hours each) followed by embedding in araldite resin at 60°C for 48 hours.
The prepared cell clusters were cut into ultrathin sections with an ultramicrotome, stained with 1% uranyl acetate and 0.2% lead citrate, and then observed under TEM and photographed. The fluorescence of the first portion was recorded without light using the multi-scan Spectrum (Infinite M200; TECAN, Männedorf, Switzerland), at 488 nm excitation and 525 nm emission. The cell viability of the other portion was tested using the CCK-8 kit. For each sample, the ratio of fluorescence intensity and cell viability was measured to determine the intracellular production of ROS.
Detection of mitochondrial membrane potential (MMP) change
MMP was investigated using the fluorescent lipophilic cationic dye JC-1. Briefly, Raji and K562 cells were collected after treatment with rituximab (23.5 µg/mL), Fe 3 O 4 @DMSA, and Fe 3 O 4 @DMSA@Ab (50 µg[Fe]/mL) for 24 hours (or 72 hours). Cell clusters were then incubated with JC-1 at 37°C for 20 minutes. The fluorescence intensity of cell samples was assayed after washing with RPMI-1640 (three times) using flow cytometry (CaliburTM; BD Biosciences).
Western blot analyses
Following treatment, the cell lysates of all samples were collected and analyzed by western blotting to detect the levels of Bcl-2 and Bax proteins. The concentration of the cell lysate was measured using a protein assay kit. The primary antibodies against Bcl-2 and Bax were used in this study. The secondary antibody was horseradish peroxidase conjugated anti-rabbit IgG. All samples were separated on SDS-PAGE gels and transferred electrophoretically to polyvinylidene difluoride membranes according to standard procedures. After blocking with tris-buffered saline containing 0.1% Tween ® 20 and 5% non-fat milk at room temperature for 2 hours, the membrane was incubated overnight with the primary antibody (1:1,000) at 4°C. After washing and subsequent blocking, the membrane was incubated with peroxidase conjugated secondary antibody (1:500) for 2 hours at room temperature, and subsequently stained with diaminobenzidine. Anti-β-actin was used as a control to ensure equal loading. Detection was performed using an enhanced chemiluminescence kit and an ECL system. raji cell apoptosis under a MF 
statistical analysis
Statistical analysis was performed using Graph pad 5.0 and Origin 8.0 software packages. Measurements of each treatment were repeated at least three times. The data obtained are presented as mean ± standard deviation (SD). Statistical comparisons were computed using two-or three-way ANOVA or an unpaired t-test. The data were considered significant at P-values,0.05 (*) or highly significant at P,0.01 (**).
Results and discussion synthesis and characterization of Fe 3 O 4 @ DMsa@ab nanoprobes
Among all the methods to synthesize Fe 3 O 4 nanoparticles, co-precipitation is the classical and most efficient chemical pathway. 33 In this paper, co-precipitation was used to prepare OA modified Fe 3 O 4 nanoparticles. The Fe 3 O 4 @OA nanoparticles were dispersed in n-hexane for their oil-solubility. However, they needed to be converted into the aqueous phase for further biological applications. Thus, DMSA was chosen to exchange OA on the surface of the nanoparticles. DMSA 34 Its metal chelating agent, which forms strong complexes with Fe 3 O 4 nanoparticles, allowed us to obtain a stable colloid in water, as indicated by monitoring hydrodynamic size variation for 35 days ( Figure S2A ). DMSA was found to form polydisulfide species (DMSAox) 4 on the surface of nanoparticles. 35 Furthermore, part of the -COOH groups remained free, which could be used for coupling antibodies. 36 The process of synthesis of nanoparticles and nanoprobes is shown in Figure 1A . TEM results show that the is the density of Fe 3 O 4 . It is obvious that R Rituximab/ Fe o 3 4 represents the number of rituximab molecules conjugated on the surface of one Fe 3 O 4 nanoparticle, which is about 1.
Fe 3 O 4 @DMsa@ab nanoprobe specifically targets CD20
It is well known that expression of the integral membrane protein CD20 is found on pre-, naïve, and mature B cells in malignancies but not on plasma cells or early pro-B cells. 38 CD20 is an ideal target for rituximab therapy because of its presence in the majority of B-cell lymphomas. 39 The process of Fe 3 O 4 @DMSA@Ab nanoprobe targeting and staining is shown in Figure 2A . CD20 expression on Raji cells was detected using a T/B cell lymphoma immunohistochemical double-dye diagnostic kit ( Figure 2B[b] ).
The rituximab immobilized on the surface of Fe 3 O 4 @ DMSA nanoparticles was captured by CD20 on the Raji cell Figure S3 ). This is consistent with previous studies where CD20 is not internalized after antibody binding. 41, 42 Fe 3 O 4 @DMSA nanoparticles were located neither in the cytoplasm nor in the cytomembrane of Raji cells.
K562 cells were found to phagocytize Fe 3 O 4 @DMSA nanoparticles. The lighter blue indicates that the uptake of Fe 3 O 4 @DMSA@Ab nanoprobes by K562 cells was less than the uptake of Fe 3 O 4 @DMSA nanoparticles. This is likely because the nanoprobes were unrecognizable to the K562 cells, and the antibody conjugation and BSA blocking reduced the non-specific adsorption of nanoparticles. This result is also verified by TEM analysis ( Figure 2C(a and b) ). To exclude the uptake effect of living cells, Raji and K562 cells were collected and fixed on slides with paraformaldehyde after centrifugation. The blue around the Raji cells indicates that the nanoprobes were labeled on the cell surface ( Figure 2B(c) ). There is no blue staining in K562 cells due to the absence of CD20 protein ( Figure 2B(f) ).
Imaging of Fe 3 O 4 @DMSA or Fe 3 O 4 @DMSA@Ab-labeled Raji cells and K562 cells was also performed on a clinical magnetic resonance scanner (MRI). The relaxation rate (1/T2) values of cell phantoms changed with increasing Fe concentration ( Figure 2D ). Raji cells incubated with Fe 3 O 4 @DMSA@Ab had the highest relaxation rate for specific binding and subsequent aggregation of nanoparticles on the cell surface after co-incubation. 43, 44 With increasing nanoprobe dosages, they were more bound onto Raji cell membrane, leading to stronger MR signal. This result is consistent with the Prussian blue staining ( Figure S3) . Meanwhile, the nanoprobe aggregation on the surface of cell membrane also contributed to the enhanced MR signal. alone, 45 Fe 3 O 4 @DMSA@Ab displayed stronger cytotoxicity to Raji cells, and there was a statistically significant difference between the rituximab and Fe 3 O 4 @DMSA@Ab groups (P,0.05) in 24 hours ( Figure 3A ) and 72 hours ( Figure S5A ).
The Fe 3 O 4 @DMSA nanoparticles did not notably alter the Raji cell viability at various concentrations (Raji cell viability .90%). These results (Figures 3 and S5) revealed that none of the agents had a significant influence on K562 46 and rituximab and Fe 3 O 4 @DMSA used for comparison. Fluorescence microscopy images of the dual stained Raji and K562 cells are presented in Figure 3C . The results show that live Raji cells were stained green due to AO uptake and their numbers decreased upon treatment with rituximab or Fe 3 O 4 @DMSA@Ab, which is consistent with the CCK-8 data. It can be observed that there is an obvious increase of orange cells in the Fe 3 O 4 @DMSA@Ab-treated Raji cell group for the uptake of EB, which can be attributed to cell membrane perforation during apoptosis. In K562 cells, there were no significant changes in green cell numbers for all four group, indicating the non-toxicity of nanoparticles and nanoprobes to K562 cells without CD20 expression ( Figure 3C As a second messenger, calcium plays an important role in signal transduction and the regulation of cell activity. Evidence has shown that calcium may be related to apoptosis. 47, 48 Studies support the hypothesis that CD20 is a central component of the calcium ion channel. 39 The transmembrane structure and homotypic aggregation of CD20 itself after cross-linking with antibodies forms an ion channel. 39, 49 Intracellular Ca 2+ concentration is known to be related to CD20 expression level while the cell is in a resting state. 50, 51 Perturbation of Ca 2+ homeostasis triggers apoptosis following the binding of CD20 with rituximab. 16 We hypothesized that the possible mechanism of pro-apoptosis is related to Ca 2+ , ROS, and ΔΨm ( Figure 4A ). For this, intracellular calcium was detected using 
Fe 3 O 4 @DMsa@ab nanoprobes trigger rOs generation and mitochondrial depolarization
ROS consist of oxidation molecules, ions, and free radicals. They exist widely in the human body and play important roles in most physiological and pathological processes. Intracellular ROS at high concentrations typically lead to a cytotoxic event. 52 Raji cells exposed to Fe 3 O 4 @DMSA@ Ab nanoprobes show a significant (P,0.001) increase in ROS generation after 24 hours ( Figure 4D ) and 72 hours ( Figure S6C ). Moreover, ROS generation in the Fe 3 O 4 @ DMSA@Ab nanoprobe group was two times greater than that in the rituximab group, resulting in stronger cytotoxicity. Notably, Fe 3 O 4 @DMSA nanoparticles also increase the levels of ROS in Raji cells, but no significant influence is observed in K562 cells, likely due to differences in their oxidative stress reactions with Fe 3 O 4 @DMSA nanoparticles. 53 The ROS level in each group showed no obvious changes on K562 cells after culturing for 24 hours ( Figure 4D ) and 72 hours ( Figure S6C ).
The apoptosis of Raji cells under the physical mixture of rituximab and Fe 3 O 4 @DMSA nanoparticles was tested to evaluate the effect of Fe 3 O 4 @DMSA@Ab nanoprobe. As shown in Figure 4E , Raji cell apoptosis was not markedly increased in the physical mixture of rituximab and Fe 3 O 4 @ DMSA nanoparticles group than in the free rituximab group, which was also much lower than that in the Fe 3 O 4 @DMSA@ Ab nanoprobe group.
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song et al , Bax, and other triggers could mediate the opening of mitochondrial permeability transition pores (MPTP), 53 inducing dissipation of ΔΨm and rupture of the mitochondrial outer membrane to release proteins. 54 The mitochondrial damage in turn leads to uncontrolled ROS formation. ΔΨm can be detected by the fluorescent JC-1 assay. 55 JC-1 can easily enter the mitochondria in normal cells (driven by ΔΨm), where it aggregates, emitting red fluorescence. When the ΔΨm collapses, JC-1 diffuses from mitochondria to the cytoplasm where it exists as a green-fluorescent monomer. Disruption of ΔΨm is considered to signal the start of the apoptotic process. 54, 56 The scatter plots in the right upper quadrant represent high ΔΨm (Figure 4F control group) . Upon loss of red fluorescence, the scatter plots are shifted to the right lower quadrant indicating a decrease in ΔΨm.
It is observed that Fe 3 O 4 @DMSA@Ab induces a more obvious drop of ΔΨm in Raji cells compared to the rituximab and Fe 3 O 4 @DMSA groups, which was clearly detected after incubation for 24 hours ( Figure 4F ) and 72 hours ( Figure S6D ). In contrast, K562 cells used as a negative control did not suffer any changes in their ΔΨm when exposed to similar treatments, indicating that there was no mitochondrial damage and that the K562 cells remained vital after incubation for 24 hours ( Figure 4F ) and 72 hours ( Figure S6D ).
Fe 3 O 4 @DMsa@ab nanoprobes reduce the expression of Bcl-2 protein after treatment
The presence of Bcl-2 family proteins in the mitochondrial membrane has a functional connection. 57 Bcl-2 can protect the cell from apoptosis by preventing mitochondrial disruption. 54, 57 Bax, a pro-apoptotic protein targets the mitochondrial membrane and can induce mitochondrial membrane damage and cell death without caspase activation. 58 Evidence suggests that Bax together with other proteins can form channels with a larger pore size in the outer mitochondrial membrane. 59, 60 It is also reported that rituximab can inhibit the signaling pathways of p38 MAPK, NF-Kb, and Akt, which can inhibit the expression of Bcl-2.
61-63 Therefore, it is interesting to investigate the change in Bax/Bcl-2 upon treatment with Fe 3 O 4 @DMSA@Ab, thereby reducing their positive influence on apoptosis. The expression of antiapoptotic protein Bcl-2 in Raji cells treated with Fe 3 O 4 @ DMSA@Ab was markedly reduced compared with other groups, however, the expression of pro-apoptosis protein Bax was increased ( Figure 5 ), suggesting that the nanoprobes can induce apoptosis in Raji cells. Meanwhile, Bcl-2 and Bax are nearly unchanged among the four groups in K562 cells.
Fe 3 O 4 @DMsa@ab nanoprobes enhanced raji cell apoptosis under a MF
In resting cells, CD20 multimers (probably at least tetramers) are distributed in mini-lipid raft domains of the cytomembrane. Binding of the anti-CD20 antibody causes clustering of CD20 multimers and their transfer to large lipid rafts, resulting in a CD20-mediated signaling cascade. 39 These signals include activation of tyrosine protein kinase, influx of Ca 2+ , and phospholipase Cγ2 (PLCγ2) phosphorylation.
11
CD20 cluster formation is also reported to increase with the addition of a secondary antibody, which acts as a bridge to crosslink the CD20 antibodies. The secondary antibody was not added in our experiment, whereas Raji cell apoptosis was increased in the Fe 3 O 4 @DMSA@Ab group. The magnetic dipole interactions among these nanoprobes after binding with CD20, which led to form nanoprobe clusters and CD20 clusters, may be one of the important causes of apoptosis. 64 These nanoprobe clusters exhibit large magnetic dipole moments compared to a single nanoprobe, which is inclined to form larger aggregates. Conversely, when the contact distance of nanoprobes is too large, the weak magnetic dipole interactions between nanoprobes are not sufficient to result in cluster formation. We therefore investigated whether apoptosis in Raji cells treated with magnetic Fe 3 O 4 @DMSA@Ab nanoprobes increases upon exposure to a MF. As per the schematic illustration in Figure 6A , Fe 3 O 4 @ DMSA@Ab was incubated with Raji cells for 12 hours, and they were captured by CD20 on the cell membrane. Raji cells were collected after centrifugation to remove the free Figure 6B ).
Based on these results, we hypothesized the possible mechanism of pro-apoptosis induced by Fe 3 O 4 @DMSA@Ab nanoprobes ( Figure 4A ). The clusters of CD20 and Fe 3 O 4 @ DMSA@Ab nanoprobes induced by the magnetic dipole lead to increased intracellular Ca 2+ and subsequently induce depolarization of ΔΨm, mitochondrial damage, and uncontrolled ROS formation, which cause irreversible cell apoptosis. Meanwhile, the downregulation of Bcl-2 and upregulation of Bax further promote the dissipation of ΔΨm and apoptosis generation. The magnetic dipole interaction and homotypic adhesion can be enhanced by MF leading to accelerated Raji cell apoptosis. A possible explanation is that driving 
